Death does matter - Cancer risk in patients with end-stage renal disease: A nationwide population-based study with competing risk analyses

Medicine (United States)

Volumn 95, Issue 3, 2016, Pages

  Weng, Shih Feng ^a   Chiu, Yu Hsien ^a   Jan, Ren Long ^b,c   Chen, Yi Chen ^b   Chien, Chih Chiang ^b,d   Wang, Jhi Joung ^b   Chu, Chin Chen ^b,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^e CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DIALYSIS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; NEWBORN; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TAIWAN; AGE; CASE CONTROL STUDY; CHILD; CHRONIC KIDNEY FAILURE; MORTALITY; NEOPLASMS; PRESCHOOL CHILD; RISK ASSESSMENT; RISK FACTOR; SURVIVAL ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN; YOUNG ADULT;

EID: 84973484030     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002512     Document Type: Article

References (25)

1. Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer? J Nephrol. 2008;21:166-174.
2. Schollmeyer P, Bozkurt F. The immune status of the uremic patient: hemodialysis vs CAPD. Clin Nephrol. 1988;30(Suppl 1):S37-S40.
3. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93-99.
4. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol. 2003;14:197-207.
5. Lee JE, Han SH, Cho BC, et al. Cancer in patients on chronic dialysis in Korea. J Korean Med Sci. 2009;24(Suppl):S95-S101.
6. Ota K, Yamashita N, Suzuki T, et al. Malignant tumours in dialysis patients: a nationwide survey. Proc Eur Dial Transplant Assoc. 1981;18:724-730.
7. Chang CH, Yang CM, Yang AH. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer. 2007;109:1487-1492.
8. Stewart JH, Vajdic CM, van Leeuwen MT, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 2009;24:3225-3231.
9. Lin HF, Li YH, Wang CH, et al. Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transplant. 2012;27:1585-1590.
10. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46-55.
11. Jones ME, Swerdlow AJ. Bias in the standardized mortality ratio when using general population rates to estimate expected number of deaths. Am J Epidemiol. 1998;148:1012-1017.
12. Liang JA, Sun LM, Yeh JJ, et al. The association between malignancy and end-stage renal disease in Taiwan. Jpn J Clin Oncol. 2011;41:752-757.
13. Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis. Br J Cancer. 2004;91:1229-1235.
14. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004;10:1956-1962.
15. Kuk D, Varadhan R. Model selection in competing risks regression. Stat Med. 2013;32:3077-3088.
16. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389-2430.
17. Southern DA, Faris PD, Brant R, et al. Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Eepidemiol. 2006;59:1110-1114.
18. Jason PF, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94: 496-509.
19. Kohl M, Plischke M, Leffondre K, et al. PSHREG: a SAS macro for proportional and nonproportional subdistribution hazards regression. Comput Methods Programs Biomed. 2015;118:218-233.
20. Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med. 2006;260:255-262.
21. Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol. 2007;22:92-98.
22. Henderson WA, Shankar R, Gill JM, et al. Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat. 2010;17:59-64.
23. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538.
24. Hwang JC, Weng SF, Weng RH. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study. Jpn J Clin Oncol. 2012;42: 780-786.
25. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296: 2823-2831.